Azaya Therapeutics, Inc. Initiates Bioequivalency Study for Regulatory Approval of ATI-0918, a Liposomal Formulation of Doxorubicin Hydrochloride
10/24/2012 9:39:22 AM
More...
|
Azaya Therapeutics, Inc. Reports Results of Phase I Clinical Trial
6/13/2012 10:05:23 AM
More...
|
ResearchPoint & Azaya Therapeutics, Inc. Announce First Patient Enrolled in Phase I Clinical Study
1/26/2010 9:35:50 AM
More...
|
SATAI Announces $1.045 Million Emerging Technology Fund Investment in Azaya Therapeutics, Inc.
9/30/2009 9:26:01 AM
More...
|
Azaya Therapeutics, Inc. Initiates Collaboration With National Cancer Institute in Nanoparticle Characterization
3/10/2009 8:51:07 AM
More...
|
Azaya Therapeutics, Inc. Licenses Promising Treatment for Head and Neck Cancers
9/3/2008 8:35:10 AM
More...
|
Azaya Therapeutics, Inc. Elects Ze'ev Shaked, Ph.D., to Board of Directors
5/31/2007 5:20:04 PM
More...
|
Azaya Therapeutics, Inc. Patents Nanotherapy Breakthrough
3/12/2007 3:36:38 PM
More...
|
Company Profile For Azaya Therapeutics, Inc.
10/19/2005 5:08:53 PM
More...
|